Reconstruction of Disease Pathology for Drug Discovery: Focus on Respiratory Diseases (Asthma and COPD)
- Broadcast Date:
Monday, October 15, 2012
11 AM ET
REGISTRATION IS FREE
In common diseases, efficient patient stratification, drug target identification, and evaluation of drug efficacy biomarkers require a fundamental understanding of the underlying biology. Disease biology can be reconstructed from scattered experimental literature as a set of specific pathology and normal perturbed pathways in a tissue and cell type specific context. In the case of asthma and COPD, the context specificity is particularly complex, as up to a dozen different cell types are involved in each disease.
Disease biology can be represented both at the level of pathology pathways (mechanistic level) and molecular alterations (gene expression and protein biomarkers) linked to the disease (causal level). Integration of both levels is critical, primarily due to high genetic heterogeneity of human populations. As a result, clinically identical disease onsets are usually associated with very different sets of molecular markers and targets in different patients. The properly reconstructed disease pathways unite this molecular diversity and can be used for patient cohort selection in clinical trials, new target discovery, understanding drug mechanisms of action (MOA,) and other applications.
In the Webinar, Respiratory Disease Experts and Thomson Reuters Will Discuss
- Different aspects of asthma and COPD biology and challenges in disease research
- Applicability of disease pathway analysis tools in clinical and fundamental disease research.
- Main features and content of the ongoing MetaMiner Respiratory Diseases project
- Case studies featuring use of disease reconstruction in drug discovery
- Industry member perspective on disease partnerships in the respiratory area
In This Webinar You Will Learn
- What the main challenges in asthma and COPD disease research are
- Why a fundamental understanding of disease mechanisms is important for clinical applications
- How asthma and COPD biology can be reconstructed at different levels
- How respiratory disease pathways can be used for OMICs data analysis and its applications (target identification, biomarker discovery, patient stratification, and others)
Who Should Attend
- Respiratory area biologists
- Scientists using bioinformatics
- Therapy area leads
- Genomics and proteomics scientists
- Drug development scientists
- Physicians using genomic data for patient care
A live Q&A session will follow the presentations,
offering you a chance to pose questions to our expert panelists.